(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2006 (18.05.2006)

PCT

(10) International Publication Number
WO 2006/050732 A3

(51) International Patent Classification:
C12N 15/11 (2006.01) *A61P 35/00* (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/DK2005/000719

(22) International Filing Date:
9 November 2005 (09.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2004 01728 9 November 2004 (09.11.2004) DK
60/626,561 9 November 2004 (09.11.2004) US

(71) Applicant *(for all designated States except US)*: **SANTARIS PHARMA A/S** [DK/DK]; Bøge Allé 3, DK-2970 Hørsholm (DK).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KJÆRULFF, Lene Sønderbye** [DK/DK]; Krohaven 9, St. Lyngby, DK-3320 Skævinge (DK). **ASKLUND, Marlene** [DK/DK]; Forchammersvej 33, 4.th., DK-1920 Frederiksberg C (DK). **WESTERGAARD, Majken** [DK/DK]; Ellebakken 5, DK-3460 Birkerød (DK). **ROSENBOHM, Christoph** [DK/DK]; Kirsebærlunden 25, 3460 Birkerød (DK). **WISSENBACH, Margit** [DK/DK]; Endrup Byvej 5, DK-3480 Fredensborg (DK). **HANSEN, Bo** [DK/DK]; Nøddehaven 33, DK-3500 Værløse (DK).

(74) Agent: **INSPICOS A/S**; Bøge Allè 3, P.O. Box 45, DK-2970 Hørsholm (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*

(88) Date of publication of the international search report:
31 May 2007

[Continued on next page]

(54) Title: LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER





(57) Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula ^{Me}5'- (^{Me}Cx)(Tx,) ^{Me}CXAsAstscscsastsgsgs ^{Me}CXAX (Gx) (c)-3', and preferably of the general formula 5'- ^{Me}CXTX), ^{Me}CXAsastscscsastsgsgs ^{Me}CxAx Gx c-3', wherein capital letters designate an LNA nucleotide analogue selected from β -D-oxy-LNA, β -D-thio-LNA, β-D-amino-LNA and a-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development *in vivo*.The LNA oligonucleotides are superior to other LNA oligonucleotides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

WO 2006/050732 A3

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.